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Abstract: HIV-associated lymphoproliferative disorders represent a heterogeneous group of 
diseases, arising in the presence of HIV
of  HIV-associated  lymphoma  is  significantly  higher  c
population and it continues to be relevant even after the wide availability of highly active 
antiretroviral therapy (HAART) (1). Moreover, they still represent one of the most frequent 
cause  of  death  in  HIV-infected  patients.
involved in human lymphomagenesis, particularly in HIV immunocompromised patients. It 
has  been  largely implicated in  the development of  B
Burkitt  lymphoma (BL),  Hodgkin 
primary  central  nervous  system  lymphoma  (PCNSL),  nasopharyngeal  carcinoma  (NC). 
Virus-associated lymphomas are becoming of significant concern for the mortality of long
lived HIV immunocompromised patients
AIDS-related  lymphomas  is  an  important  field  in  cancer  chemotherapy.  Detailed 
understanding of the EBV  lifecycle and related cancers at the molecular level is required for 
novel  strategies  of  molecular-
lymphoma with EBV infection of the tumor clone has several pathogenetic, prognostic and 
possibly therapeutic implications which are reviewed herein. 
Epidemiology  of  AIDS  related  lymphomas
Registry  linkage  studies  in  the  pre
antiretroviral therapy (HAART) era found that the 
incidence  of  high  grade  B-cell  non
lymphoma (NHL) in HIV-infected individuals was 
60-200  times  higher  than  that  in  HIV
persons.  The  introduction  of  HAART  during  the 
mid-1990s  has  been  associated  with  a  fall  in 
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associated lymphoproliferative disorders represent a heterogeneous group of 
diseases, arising in the presence of HIV-associated immunodeficiency. The overall prevalence 
associated  lymphoma  is  significantly  higher  compared  to  that  of  the  general 
population and it continues to be relevant even after the wide availability of highly active 
antiretroviral therapy (HAART) (1). Moreover, they still represent one of the most frequent 
infected  patients. Epstein–Barr  virus  (EBV),  a 
involved in human lymphomagenesis, particularly in HIV immunocompromised patients. It 
has  been  largely implicated in  the development of  B-cell lymphoproliferative disorders  as 
Burkitt  lymphoma (BL),  Hodgkin disease  (HD), systemic non  Hodgkin lymphoma (NHL), 
primary  central  nervous  system  lymphoma  (PCNSL),  nasopharyngeal  carcinoma  (NC). 
associated lymphomas are becoming of significant concern for the mortality of long
lived HIV immunocompromised patients, and therefore, research of advanced strategies for 
related  lymphomas  is  an  important  field  in  cancer  chemotherapy.  Detailed 
understanding of the EBV  lifecycle and related cancers at the molecular level is required for 
-targeted  cancer  chemotherapy  The  linkage  of  HIV
lymphoma with EBV infection of the tumor clone has several pathogenetic, prognostic and 
possibly therapeutic implications which are reviewed herein. 
Epidemiology  of  AIDS  related  lymphomas: 
Registry  linkage  studies  in  the  pre-highly  active 
antiretroviral therapy (HAART) era found that the 
cell  non-Hodgkin’s 
cted individuals was 
200  times  higher  than  that  in  HIV-uninfected 
persons.  The  introduction  of  HAART  during  the 
1990s  has  been  associated  with  a  fall  in 
incidence  of  opportunistic  infections  and  AIDS
associated malignancies, including NHL
Within the  French  Hospital  Database  on  HIV 
Infection (FHDH), the incidence of systemic NHL 
has decreased between 1993 and 1994 and between 
1997 and 1998, from 8.6 per 1,000 to 4.3 per 1,
person-years,  respectively 
same  cohort  was  2.8  per  1,000  person
2006. This is consistent with reports of decreased 
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population and it continues to be relevant even after the wide availability of highly active 
antiretroviral therapy (HAART) (1). Moreover, they still represent one of the most frequent 
Barr  virus  (EBV),  a  γ-Herpesviruses,  is 
involved in human lymphomagenesis, particularly in HIV immunocompromised patients. It 
cell lymphoproliferative disorders  as 
disease  (HD), systemic non  Hodgkin lymphoma (NHL), 
primary  central  nervous  system  lymphoma  (PCNSL),  nasopharyngeal  carcinoma  (NC). 
associated lymphomas are becoming of significant concern for the mortality of long-
, and therefore, research of advanced strategies for 
related  lymphomas  is  an  important  field  in  cancer  chemotherapy.  Detailed 
understanding of the EBV  lifecycle and related cancers at the molecular level is required for 
targeted  cancer  chemotherapy  The  linkage  of  HIV-related 
lymphoma with EBV infection of the tumor clone has several pathogenetic, prognostic and 
incidence  of  opportunistic  infections  and  AIDS-
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1,2.
the  French  Hospital  Database  on  HIV 
Infection (FHDH), the incidence of systemic NHL 
has decreased between 1993 and 1994 and between 
1997 and 1998, from 8.6 per 1,000 to 4.3 per 1,000 
years,  respectively 
3;  the  incidence  in  the 
er  1,000  person-years  in 
2006. This is consistent with reports of decreased Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
incidence of HIV-related NHL in the post HAART 
era  from  the  U.K.,  Australia,  California
4. 
Nevertheless,  the  incidence  ratio  of  NHL  still 
remains relatively high in HIV-infected patients (5-
6). On the contrary, the incidence of PCNSL has 
dramatically  decreased  since  the  introduction  of 
HAART
4.  Concerning  HD,  the  relative  risk  is 
increased, ranging from five- to 25-fold compared 
to that of the general population
7,8,9.
Approximately  1–6%  of  HIV  infected  patients 
develop lymphoma each  year. In 2006 the World 
Health Organization estimated 39.5 million people 
were living with HIV and that during that year there 
were 4.3 million new infections with 65% of these 
occurring  in  sub-Saharan  Africa.  Major  increases 
were also seen in Eastern Europe and Central Asia, 
where it appears that infection rates have risen by 
more  than  50%  since  2004.  Many  of  those  with 
retroviral infection will either have limited access to 
HAART  or  will  be  unaware  of  their  HIV  status. 
Therefore  the  incidence  of  HIV-associated 
lymphomas will most likely increase globally in the
years to come 
10,11.
Categories  of  HIV-associated  lymphoma:  The 
WHO  (12)  classification  of  lymphoid  neoplasms 
categorises  (Table  1)  the  HIV-associated 
lymphomas into:
1. Those  also  occurring  in  immunocompetent 
patients,  as  Burkitt  and  Burkitt  –like 
lymphomas, Diffuse large B-cell lymphomas 
Centroblasti  and  Immnunoblastic  (including 
primary  CNS  Lymphoma),  Extranodal 
marginal  zone  lymphoma  of  Malt  Type, 
Peripheral  T-cell  lymphoma,  Classical 
Hodgkin  lymphoma  (80%  of  all  HIV 
lymphomas);
2. Those  occurring  more  specifically  in  HIV-
positive  patients  as  Primary  Effusion 
Lymphoma
4 and Plasmablastic Lymphoma of 
oral cavity type and other variants (3%);
3. Those  also occurring  in  patients  with  other 
forms of immunosuppression as Polymorphic 
B-cell  lymphoma  (PTLD-like)  (5%  of  all 
HIV lymphomas). 
Immunodeficiency  and  pathogenesis  of 
lymphomas in HIV-infected individuals: HIV is a 
lentivirus  of  the  retrovirus  family,  and  thus 
integrates  into  host  chromosomal  DNA  using  a 
DNA intermediate. It has been generally believed 
that  integration  of  HIV  is  a  random process,  and 
therefore this process is not in itself oncogenic
13.
Table 1.  Classification of HIV-associated lymphomas
1. Lymphoma also occurring in immunocompetent 
patients:
a. Burkitt and Burkitt-like Lymphoma
b. Diffuse large B-cell lymphoma
i. Centroblastic
ii. Immunoblastic (including primary CNS lymphoma)
c. Extranodal marginal zone lymphoma of Malt type
d. Peripheral T-cell lymphoma
e. Classical Hodgkin Lymphoma
2. Lymphoma occurring more specifically in Hiv positive 
patients
a. Primary effusion Lymphoma
b. Plasmablastic lymphoma of the oral cavity type
3. Lymphoma also occurring in other immunodeficiency 
states
a. Polymorphic B-cell lymphoma (PTLD-like)
Accordingly  with  this  theory  is  the  fact  that 
Southern  blot  analysis  of  HIV-associated 
lymphomas has failed to detect HIV sequences 
14, 
with rare reports of clonal integration restricted to 
T-cell  neoplasms
15.  Although  the  neoplastic  cells 
are not themselves infected with HIV in most cases, 
in  vitro  evidence  suggests  that  HIV  does  have 
transforming  properties.  Laurence  and  Astrin 
showed that HIV infection of B-cell lines derived 
from  EBV-seropositive  individuals  led  to  B-cell 
immortalisation,  dysregulation of  MYC,  and 
activation  of  EBV
7.  Certain  HIV  gene  products, 
particularly Tat, have been implicated as potentially 
oncogenic in their role as transactivators of cellular 
genes, such as IL6 and IL10 
7. Tat protein can more 
directly  interfere  with  cell  cycle  control  by 
interaction with the  regulatory protein Rb2/p130
8. 
This role of the Tat protein has been proposed as a 
significant factor in the pathogenesis of HIV-related 
Burkitt lymphoma
8. 
The  predominant  contribution  of  HIV  to 
lymphoma pathogenesis is believed to  be through 
indirect  mechanisms.  The  increased  risk  for 
lymphoma among HIV-infected individuals appears 
related to multiple factors, including duration and 
degree  of  immunosuppression,  induction  of 
cytokines  leading  to  B-cell  proliferation,  and 
opportunistic  infections  with  oncogenic 
herpesviruses such as EBV and HHV8
14.Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
HIV-associated  malignancies  are  commonly 
considered to be the result of diminished immune 
surveillance  against  viruses  and  virus-infected 
tumor cells. The beneficial effects of HAART on 
these tumors have therefore been interpreted as the 
result  of  drug-mediated  HIV  suppression  and 
immune reconstitution.
This  is  supported  by  several  findings.  For 
example, EBV load is increased in patients before 
development of B-cell lymphoma, whereas specific 
immune  responses  against  the  virus  are 
decreased
16,17,18.  The  relative  risk  of  AIDS-
associated malignancies increases progressively as a 
function of the progressive decline of CD4+ T-cell 
counts
19.  Nevertheless,  the  relation  between 
immune deficiency and tumor development is not 
straightforward.
In  fact,  only  certain  types  of  AIDS-associated 
tumors  arise  in  immunodeficient  patients.  In 
particular, NHL subtypes including Immunoblastic 
lymphomas and PCNSL, along with Burkitt’s-like 
lymphomas, typically develop in patients with very 
low  CD4+  T-cell  counts.  On  the  other  hand,  the 
incidence  of  other  NHL  subtypes  such  as 
Centroblastic Diffuse Large-cell Lymphomas, along 
with  classic  Burkitt’s  Lymphoma,  Hodgkin’s 
disease, cervical cancer and, most notably, Kaposi’s 
sarcoma,  increases  in  patients  who  have 
significantly higher CD4+ T-cell numbers
9,20,21. 
The overall risk of tumour development is very 
high  in  HIV-infected  individuals,  but  the  relative 
increase  in  tumor risk  with  stepwise  decreases in 
CD4+ T-cell counts is only marginal
22. It has been 
observed  that  the  risk  of  tumor  development 
increases  steeply  as  CD4+  T-cell  counts  decline 
below a certain threshold, nevertheless, once below 
this threshold, cancer risk becomes less dependent 
on further CD4+ T-cell loss
19.
However,  evidence  indicates  that  this 
hypothetical  CD4+  T-cell  count  threshold  can  be 
very  high  in  certain  individuals.  In  particular,  in 
HIV-infected  homosexual  men, the  incidence  rate 
of Kaposi’s sarcoma increases by more than 1000-
fold before a consistent CD4+ T-cell decline
20. So, 
CD4+  T-cell  loss  and  consequent  immune 
deficiency  cannot  fully  explain  the  increased 
incidence of certain malignancies in HIV-infected 
individuals. Indeed, several recent studies show that 
immune  activation  causes  and  precedes  the 
development  of  immune  deficiency  in  HIV 
infection
23,24,25.  Sustained  and  uncontrolled  HIV 
replication leads to continuous antigenic stimulation 
and  to  chronic T-cell activation and proliferation, 
which,  in  turn,  generates  a  continuous  drain  of 
naive and memory T  cells that become activated, 
proliferate, die by apoptosis or re-enter the pool of 
memory T cells. However, this exhausts the pool of 
naive T  cells,  impairing  the  capacity  to  mount 
antigen-specific immune responses
22,23,24,25.
Several other studies also indicate that immune 
activation,  rather  than  immune  deficiency,  is  the 
key factor in the initiation of B-cell lymphomas. In 
particular, AIDS-associated B-cell lymphomas are 
described  to  be  preceded  by  chronic  antigen 
dependent B-cell stimulation leading to a persistent 
and  generalized  lymphadenopathy    that,  in  turn, 
promotes  the  clonal  expansion  of  pre-neoplastic 
antigen-specific B-cell populations
26,27.
Furthermore,  an  increased  EBV  load  precedes 
the  development  of  B-cell  lymphoma
17,  whereas 
extracellular Tat increases B-cell proliferation and 
induces B-cell lymphomas in mice
26,27.
The role of EBV: Regarding EBV, the percentage 
of  cases  within  each  histotypes  with  EBV  viral 
infection is variable, ranging from 60% to 100%. In 
contrast to other lymphomas, a high frequency of 
EBV  association  has  been  shown  in  HL  (80%-
100%)  tissues  from  HIV-infected  people  and  the 
EBV-transforming  protein,  EBV-encoded  latent 
membrane  protein-1  (LMP-1),  is  expressed in 
virtually all HIV-HL cases
28,29. On this basis, HL in 
HIV-infected persons appears to be an EBV-driven 
lymphoma
30.
The spectrum of lymphomas occurring in HIV-
infected  patients  includes  pathologic  subtypes 
displaying specific association with distinct viruses. 
BL  and  DLBCL-IB  with  plasmacytoid 
differentiation are often HIV associated and closely 
linked to EBV infection. 
The HIV-associated DLBCL-IB is distinct from 
other large cell lymphomas occurring in both HIV-
seropositive  and  -seronegative  patients  because 
HIV-associated  DLBCL-IB  lymphomas  display  a 
plasma cell–related phenotype.
Most  HIV-associated  lymphoproliferative 
disorders, including primary central nervous system 
lymphoma,  systemic  DLBCL  IB-plasmacytoid, 
PEL  and  its  solid  variant,  and  PBLs  of  the  oral 
cavity type, display a phenotype related to plasma 
cells and are linked to EBV infection. 
Burkitt  lymphoma:  Among  EBV-positive  high-
grade B cell Lymphomas, Burkitt Lymphoma (BL) 
occupies  a  particular  position  as  being  the  tumor 
type  in  which  EBV  was  discovered.  Burkitt  and 
Burkitt-like/atypical  Burkitt  lymphomas  make  up 
the  largest  group  of  HIV-associated  non-Hodgkin Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
lymphomas,  comprising  up  to  35–50%  of  these 
neoplasms in some studies
31.
Classification  of  these  lymphomas  in  the  HIV 
setting follows the same diagnostic criteria as are 
used  in  the  general  patient  population.  That  is,  a 
diagnosis  of  Burkitt  or  Burkitt-like  lymphoma 
requires  a  medium-sized  CD10-positive  B-cell 
population  with  a  high  proliferative  rate  and 
demonstration  of  a  translocation  involving  the 
MYC gene
12. Peripheral blood involvement is less 
common  in  HIV-infected  patients  compared  to 
HIV-negative  patients  with  Burkitt  lymphoma, 
although  it  can  occur
12,31,32.  Burkitt  lymphoma 
occurring  in  the  HIV  setting  is  characterised  by 
multiple  genetic  lesions,  with  the  relative 
significance  of  each  in  the  pathogenesis  of  this 
lymphoma  unknown.  In  addition  to  the 
translocation  involving  MYC,  point mutations  in 
regulatory regions associated with MYC and within 
the TP53 tumour suppressor gene are common
12.
In the context of HIV infection, EBV-encoded 
RNA  (EBER)  can  be  detected  by  in  situ 
hybridisation in tumor cells in about 30% of Burkitt 
lymphomas, 50–70%  of  Burkitt  lymphomas  with 
plasmacytoid  differentiation,  and  30–50%  of 
Burkitt-like lymphomas. 
Similarly  to  sporadic  or  epidemic  forms  of 
Burkitt  lymphoma,  in  HIV-associated  EBER-
positive  disease  the  viral  oncogenes  LMP-1  and 
EBNA-2 are not expressed (Table 2, Table 3). 
Although  not  essential  in  the  pathogenesis  of 
BL, EBV supports tumor development. EBNA-1, a 
viral  protein  required  for  the  replication  and 
maintenance of the latent viral episomal DNA, is 
found  consistently  in  BL  cells
33. The  presence of 
latent EBV in BL cells has been shown to promote 
genetic instability (34), suggesting a mechanism by 
which  latent  EBV  could  contribute  to  genetic 
alterations required for the development of BL.
This  is  in  contrast  to  EBER-positive 
immunoblastic DLBCL and PEL,  which do  show 
expression  of  these  EBV-associated  viral 
oncogenes. Thus EBV may not play the same role 
in  oncogenesis  in  these  different  types  of 
lymphoma.  It  is  interesting  to  note  that  although 
Burkitt  lymphoma  is  common  in  HIV-infected 
patients,  it  is  not  associated  with  other  forms  of 
immunosuppression. 
This may indicate that the oncogenic properties 
of HIV itself play a greater role in pathogenesis in 
this  highly  proliferative  tumour  compared  with 
EBV  or  that  there  are  other  mechanisms.
Dysregulation  of  cell  cycle  proteins  has  been 
implicated  in  the  development  of  Burkitt 
lymphoma.  Inactivating  mutations  of  the  tumour 
suppressor  gene  RBL2  (Rb2/p130)  are  frequently 
found in endemic Burkitt lymphoma, and are also 
found in sporadic cases
35.
By contrast, in HIV-associated cases, abnormal 
overexpression  of  wild-type  RBL2  is  seen.  This 
finding, in conjunction with studies indicating that 
the  function  of  Rb2/p130  in  the  control  of  the 
G0/G1  transition  can  be  negated  by  physical 
interaction  with  the  Tat  protein  of  HIV-1,  may 
suggest  a  direct  role  for  HIV  proteins  acting 
synergistically  with  MYC  activation  in  the 
pathogenesis of Burkitt lymphoma
36.
Diffuse large B-cell Lymphoma: As in the HIV-
negative  setting,  the  category  of  HIV  associated 
DLBCL  is  a  clinically  and  pathologically 
heterogeneous  group  Lymphomas  with  a 
predominance  of  centroblasts  have  been  termed 
centroblastic  DLBCL,  whereas  those  with  greater 
than  90%  immunoblasts/plasmablasts  have  been 
termed immunoblastic DLBCL. 
These two general morphological subtypes show 
correlation  with  certain  clinical  features  and 
molecular  profiles.  The  subtypes  occur  with 
approximate  equal  frequency  in  HIVinfected 
patients, with the relative frequency of centroblastic 
DLBCL  increasing  and  that  of  immunoblastic 
DLBCL decreasing in recent years due to advances 
in HIV therapy. Centroblastic DLBCL occurs in the 
setting  of  mild  immunosuppression,  has  a  low 
frequency  of  EBV  positivity  (30–40%)  without 
expression of LMP-1, shows a germinal centre B-
cell phenotype (expression of CD10 and BCL6, and 
lack  of  expression  of  CD138  and  MUM1),  and 
frequently shows rearrangements of the BCL6 gene. 
In  contrast,  immunoblastic  DLBCL  usually 
occurs in the context of severe immunosuppression, 
has a high frequency of EBV positivity (80–90%) 
with frequent expression of LMP-1 and EBNA-2, 
shows a non-germinal centre B-cell/activated B-cell 
phenotype (lack of expression of CD10 and BCL6, 
expression  of  CD138  and  MUM1),  and  lacks 
rearrangements of BCL6
35 (Table 2, Table 3).
The  transforming  EBV  protein  LMP-1  is 
frequently expressed
37,38. LMP-1 plays a crucial role 
in the transformation of B-lymphocytes by EBV
40. 
Thus,  LMP-1 transforms  rodent  fibroblasts
40
transgenic mice that express LMP-1 in B cells show 
increased development of B-cell lymphomas
41 and 
LMP-1 deletion mutants of EBV are compromised 
in  their  ability  to  immortalize  human  primary  B 
cells
42. LMP-1 activates the NFkB as well  as the 
JNK and p38 pathways (39,40,41), by recruitingMedit J Hemat Infect Dis 2009; 1(2); Open Journal System 
Table 2.  Immunological and EBV status in AIDS-related Lymphomas
Lymphoma Histology immunodeficiency % in  HIV EBV+ Rate Viral cofactor
Systemic AIDS-Related Lymphomas
       Burkitt Lymphoma Mild 55 EBV EBER
            Classic BL 30 30%
            BL with Plasmocitoid diffent 20 50-70%
            Atipical BL Less freq 30-50%
        Diffuse Large B-cell lymphoma 30
            Centroblastic type Mild 20 30-40%
             Immunoblastic type Marked 10 90-100% EBV LMP1
AIDS Primary CNS Lymphoma Marked < 5 100% EBV LMP1
Primary effusion Lymphoma Marked < 5 90% EBV
Plasmablastic lymphoma oral cavity < 5 50% LMP1
Hodgkin Disease Classical Marked 100% LMP1 LMP2A
cellular  TRAF  1-3  and  TRADD  molecules  to  2 
short  sequence  motifs,  CTAR-1  and  CTAR-2, 
respectively,  in  the  cytoplasmic  domain  of  the 
LMP-1 molecule
43,44,45.
In B cells, LMP-1 increases the expression of the 
antiapoptotic proteins A20 and bcl-2, the adherence 
molecule  CD54/ICAM-1,  the  cell-cycle  regulator 
p27Kip,71 and many others
46. 
In  DLBCL,  expression  of  LMP-1  correlates 
inversely with the expression of BCL6, a marker for 
germinal  center B  cells,  suggesting  that,  among 
DLBCLs, the impact of EBV LMP-1 is likely to be 
strongest  in  tumors  representing  a  post–germinal 
center  plasmacytic  differentiation  profile
47.  In 
addition, knockdown of LMP-1 in cell lines derived 
from AIDS-DLBCL results in apoptosis, indicating 
that this viral oncoprotein plays a role in lymphoma 
pathogenesis
48.
EBV-associated  DLBCLs  have  t  been 
considered  as  EBV-driven  lymphoproliferations 
occurring  in  the  context  of  a  defective  T-cell 
immunity  against  EBV.
49 However,  unlike  EBV-
driven  lymphoproliferative  disease  in  transplant 
recipients, which includes monoclonal, oligoclonal, 
as well as polyclonal B-cell proliferations, DLBCL 
is  always  monoclonal.  This  suggests  that,  in 
addition to the effects contributed by EBV LMP-1, 
additional factors such as genetic damage are likely 
to contribute to the pathogenesis of AIDS-DLBCL.
Primary CNS Lymphoma: Accounting for 15% of 
HIV-associated lymphomas, PCNSL has a reported 
incidence  of  over  1000  times  greater  than  in  the 
non-HIV  population
50.  This  is  most  likely  a 
reflection  of  the  brain  as  a  relatively  immuno-
privileged  site.    There  has  been  a  decline  in  its 
incidence  since  HAART  introduction
51,  and  it 
would confirm the strong association of this tumor 
with  severe  and  prolonged  immunosuppression.  
Clinical  presentation  results  from  neurological 
deficits related to the site of the tumor, with mental 
state disturbance and seizures more common than in 
non-HIV  PCNSL. Systemic  B  symptoms  are  also 
common
52,53.
These tumors have a tendency to occur late in 
the  course  of  HIV  infection  and  show  EBV 
association in virtually 100% of the cases
53. A few 
studies have reported that detection of EBV in the 
cerebrospinal fluid of HIV-positive patients with a 
CNS lesion infers a diagnosis of lymphoma
54,55,56. 
These lymphomas have been reported to express all 
EBV  latent  encoded  proteins  (latency  III)
57,  and 
there  are  observations  consistent  with  their 
histogenetic derivation from germinal center-related 
B cells.
58Nevertheless, the exact role of EBV in the 
pathogenesis  of  these  disorders  remains  not 
completely defined (Table 2, Table 3).Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
Table 3. Features of EBV-associated Aids-associated B-cell Lymphoma
Lymphoma EBV % EBV Latency Phenotype Cellular origin of lymphoma cells
Hodgkin L Classical 100% Type II Loss B-cell Phenotype Pre-apoptotic GC B cells
PCNSL 100% Type III BCL6- CD138+ Mum 1+ GC or post GC B cells
Burkitt Lymphoma 55% Type I BCL6+ CD10+ CD77+ GC B cell
PEL 90-100% Type I Loss B-cell Phen. CD38+ GC or post-GC B cells
DLCL-CB 30% Type I BCL6+ CD138- MUM1- Mostly GC or post-GC B cells
DLCL-IB 90% Type III BCL6- CD138+MUM1+ Mostly GC or post-GC B cells
Most patients have CD4 counts <50/uL and have 
multifocal  lesions  at  time  of  diagnosis.  Ocular 
involvement  occurs in  up to  20% of cases
59. Full 
staging at time of diagnosis is essential to exclude 
system NHL involving the  brain. MRI brain scan 
has  a  higher  diagnostic  yield  than  CT  and  is 
recommended  for suspected  intracranial  masses
60. 
Up  to  30%  of  CNS  lesions  in  HIV  patients  are 
found  to  be  PCNSL  with  toxoplasmosis  and 
progressive multifocal leukoencephalopathy making 
up  the  remaining  cases
60.  The  most  common 
histology is immunoblastic variant DLBCL.
Differentiation  between  PCNSL  and 
toxoplasmosis can be difficult, as both cause ring 
enhancing  lesions  with  mass  effect  and  oedema 
(although  PCNSL  lesions  are  more  likely  to  be 
periventricular) and up to 15% false negative rates 
for toxoplasmosis serology
61,62.
Radionuclide  scanning  has  also  been 
investigated.  PCNSL  lesions  are  avid  by 
Thallium
201 single  photon  emission  CT  and 
fluorodeoxyglucose-positron
18 emission  tomo-
graphy  (FDG-PET),  however  improve  specificity 
should be combined with PCR and is emerging as 
an alternative to brain biopsy
63,64. This needs to be 
further  validated  and  brain  biopsy  is  still  the 
definitive  diagnostic  procedure,  but  must  be 
weighed  against  a  mortality  rate  of  2–3%
64, 
particularly in the post-HAART era during which it 
seems that  EBV-DNA detection  shows  a  reduced 
negative predictive value compared to  that of the 
pre-HAART period.
In  the  new  trials  the  use  of  EBV-DNA 
measurement is used as a surrogate to brain biopsy. 
Response to  therapy may  also  be monitored with 
EBV-DNA.    There  is  no  standard  therapy  for 
PCNSL.  Whole-brain  radiation  (WBRT)  achieves 
CR  in  up  to  50%  but  this  is  not  translated  to 
increased  survival,  with median survival  no  more 
than  3  months.  Deaths  are  generally  related  to 
opportunistic  infections  due  to  overwhelming 
immunosuppression  at  time  of  diagnosis.  Even 
though many patients are unable to tolerate the full 
dose  of  radiation,  the  strongest  predictors  of 
outcome are performance status and the ability to 
deliver higher effective radiation doses.
A promising alternative to WBRT was studied in 
15 patients using single-agent MTX intravenously 
at  3g/m2.  The  mean CD4  count  in  these  patients 
was 30/uL. Almost 50% had achieved CR with a 
median survival of 19 months and a relapse rate of 
only 14%
65. There is a survival benefit associated 
with the use of cART after diagnosis
66, and there is 
evidence  that  cART  may  increase  the  radio-
sensitivity  of  B  cells  within  the  lymphoma
67,68. 
Given the very limited benefit of current modalities, 
patients should be referred to clinical trials.
Since there is universal association of EBV in 
HIV-associated PCNSL, therapeutic options which 
target the virus have been explored. In this regard it 
should be noted that EBV-specific allogeneic CTL 
have been shown to cross the blood brain barrier 
and  induce  tumour  lysis.  In  the  absence  of  an 
available  study,  either  first-line  WBRT  or 
alternatively  high-dose  MTX  with  the  option  of 
WBRT  consolidation  should  be  considered. 
Concomitant  HAART  therapy  to  enhance  the 
immune system is critical to successful outcomes
Classical  Hodgkin  lymphoma:  HL  is  the  most 
common  type  of  non-AIDS  defining  tumor.  The 
risk of developing HL in HIV patients is up to 11-
18  times  above  the  general  population
69.  It  is 
associated  with  advanced  disease  and  is  more 
common  in  the  intravenous  drug  group  than  in 
homosexual men. Its hallmark includes aggressive Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
clinical  presentation  with  systemic  B  symptoms, 
widespread non-contiguous extranodal lesions and 
frequent bone marrow involvement (in up to 50% of 
cases).  The  morphological  patterns  are  similar  to 
those  seen  in  patients  without  HIV  infection, 
although with a greater proportion of the subtypes 
(mixed cellularity, lymphocyte depleted) with less 
favourable  prognosis compared  to  the  general 
population
70. As noted above, the greater proportion 
of  mixed  cellularity  and  lymphocyte  depleted 
subtypes  appears  specifically  related  to  severe 
immunocompromise  in  HIV,  while  HIV-infected 
patients with modest immunocompromise are more 
at risk for the development of the nodular sclerosis 
subtype.
The  composition  of  the  reactive  inflammatory 
infiltrate  in  HIV-associated  HL  is  often 
characterised by a predominance of CD8-positive T 
lymphocytes  over  CD4-positive  lymphocytes,  by 
contrast with the  background in  HL without HIV 
infection
70.  This  finding  may  simply  reflect  the 
depleted  peripheral  CD4  counts  in  this  patient 
population. The cytological and phenotypic features 
of  the  Hodgkin  Reed–Sternberg  (HRS)  cells  in 
HIV-associated HL are similar to those in non-HIV 
associated HL. It has been determined that RS cells 
of all histologic categories of HIV-HD consistently 
display the BCL-6(-)/syn-1(+) phenotype and thus
reflect post-GC B cells
71.
The  HRS  cells  typically  express  CD15  and 
CD30, express CD20 in a minor subset, and lack 
expression of CD45
70 In the vast majority of HIV 
associated  HL  there  is  coincident  EBV  infection. 
The  latent  EBV  proteins  EBNA-1,  LMP-1,  and 
LMP2A are expressed in the RS cells, the malignant
cell population of this tumor
72. RS cells are derived 
from B cells that have passed through the germinal 
center,  as  shown  by  the  presence  of  somatic 
mutations  in  the  rearranged  Ig  variable  region  of 
their  immunoglobulin  genes
73 LMP2A  interferes 
with  normal  B-cell  development,  allows  BCR-
negative B cells to leave the bone marrow/colonize 
peripheral  lymphoid  organs
74,  and  induces  a 
transcriptome  pattern  in  B cells,  which resembles 
that  of  HL  RS  cells
75.  Following  EBV  infection, 
LMP2A is essential for the survival and continued 
proliferation  of  germinal  center  B  cells lacking  a 
functional  B-cell  receptor
76,77.  LMP2A  may 
therefore  promote  the  survival  of  “crippled” 
germinal  center  B  cells  and  could  thus  aid  their 
development into RS cells (Table 2, Table 3). 
LMP-1  may  also  induce  an  “HL-like” 
transcriptional program in germinal center B cells
78
Among the cellular genes up-regulated by LMP-1 in 
HL  cells  is  bmi-1,  a  polycomb  family  member 
known to cause lymphoma in transgenic mice and 
to  down-regulate  the  ATM  tumor  suppressor
79. 
EBNA-1 was shown to induce CCL-20 secretion in 
RS cell lines and to thereby promote the migration 
of regulatory T cells, which could be envisaged to 
downmodulate EBV-specific T-cell responses
80. 
This  association  with  EBV  is  considerably 
stronger  than  that  seen  in HL  in  the  non-HIV 
infected population. HIV-associated HL most often 
presents  at  an  advanced  clinical  stage,  with  B 
symptoms,  frequent  extranodal  disease,  as  bone 
marrow  localization,  and  an  aggressive  course
81. 
Unusual extranodal sites, such as the skin, lung and 
gastrointestinal tract may be involved
82. These sites 
are  essentially  never  involved  by  HL  that  is  not 
associated with HIV.
HIV-HL  patients  have  reduced  CR  rates  and 
survival  compared  with  the  HIV  negative 
population. In the early years post-HAART therapy 
the incidence of HIV-HL appeared to be in decline 
however two studies showed that the incidence may 
actually have increased
83,84. 
The post-HAART era was also associated with 
an improvement in survival which was attributed to 
virological response to antiretroviral therapy and a 
reduction in HIV-associated mortality
85. In another 
study  of  47  patients  in  the  post-HAART  era,  the 
median survival was not reached compared with 19 
months in the pre-HAART era
86,87. 
Optimal  therapy  for  HIV-HL  has not  been 
defined.  Treatment  regimes  used  are  similar  to 
those used in HL in the seronegative population
88,89. 
Primary  effusion  lymphoma  (PEL):  PEL  is  a 
distinct clinicopathological entity occurring almost 
exclusively  in  HIV-infected  patients.  This 
lymphoma  subtype comprises less than 5% of all 
HIV-associated NHL. Cases of this type were first 
described  by  Knowles  et  al  in  1989
90,  but  its 
distinctive features were not fully recognised until 
after  the  identification  of  the  Kaposi  sarcoma-
associated  herpesvirus/human  herpesvirus  8 
(KSHV/HHV8) in 1994
91,92, PEL is a distinct type 
of  B-cell  non-Hodgkin  lymphoma  (NHL)  that 
presents  most  frequently  in  body  cavities  as 
lymphomatous  effusions  without  an  associated 
tumor mass.
The  tumor  cells  have  large  round  to  irregular 
nuclei  with  prominent  nucleoli,  and  abundant 
deeply  basophilic  and  occasionally  vacuolated 
cytoplasm.  These  are  described  as 
immunoblastic/plasmablastic  or  anaplastic 
morphological  features.  Recent  studies  have Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
broadened  the  scope  of  PEL  to  include those 
presenting as a solid tumour mass with or without 
an  associated  effusion
93,94,95.  The  so-called 
‘‘extracavitary’’  or  ‘‘solid  variant’’  of  PEL  most 
commonly involves the gastrointestinal tract or soft 
tissue,  but  can  also  involve  lymph  nodes.  Some 
studies have suggested that the extracavitary variant 
of  PEL  has  a  slightly  better  prognosis  when 
compared with cases presenting with effusion
95,96.
A  defining  property  of  PEL  is  its  consistent 
association  with  KSHV  infection.  Most  cases  are 
also co-infected by EBV. It is believed that KSHV, 
rather than EBV, is a driving force in these tumors, 
as  in  PEL,  at  least  5  KSHV  viral  genes  are 
expressed,  which  provide  proliferative  and 
antiapoptotic  signals.  In  contrast,  EBV  has  a 
restricted latency pattern of gene expression in PEL, 
where  only EBNA1  and  EBERs  are  expressed
97. 
However, the viral oncoprotein LMP-1 is generally 
not expressed
94,95,96,97 (Table 2, Table 3).
The  immunophenotypic  features  of  PEL  often 
make it difficult to confirm B-cell lineage, as the 
neoplasm usually lacks expression of most B-cell 
associated antigens including CD19, CD20, CD79a 
and  immunoglobulins.  The  most  frequently 
expressed  antigens  include  those  associated  with 
activation  or  plasmacytic  differentiation,  such  as 
CD30, CD45, EMA,  CD71, MUM1,  and  CD138. 
Aberrant  expression  of  Tcell  associated  antigens
CD3 and CD7 has been reported
98,99,100,101,102.
B-cell origin of PELs, can be demonstrated by 
the  presence  of  clonal  immunoglobulin  gene 
rearrangements.  Evidence  points  toward  a  post–
germinal  center  B-cell  derivation,  as  most  PELs 
contain somatic hypermutation of Ig genes as well 
as frequent somatic hypermutation of the noncoding 
region of the BCL6 gene
103,104. Consistent with this 
notion is the expression of plasma cell markers such 
as  CD138/Syndecan-1.  Recently,  gene  expression 
analysis  of  PEL  showed  features  most  similar  to 
AIDS  immunoblastic  lymphoma  and  multiple 
myeloma,  again  indicating  a  pre–plasma  cell  or 
“plasmablastic” profile
105.
Again, the exact role of EBV has been debated; 
but the fact that both viruses are detected together in 
most of the cases suggests that EBV may act as a 
cofactor  in  the  initiating  events  (because  it  can 
immortalize  and  transform  B  cells  in  vitro  and 
HHV-8  cannot),  whereas  HHV-8  may  be  the 
driving  force  for  the  tumor
106.  With  or  without 
therapy,  PEL  is  invariably  associated  with  an 
adverse  prognosis.  There  is  limited  data  on  the 
treatment  of  PEL.  The  destruction  of  local  tissue 
despite  aggressive  therapy  leads  to  shortened 
survival
107. 
Chemotherapy  and  radiotherapy  may  result  in 
responses but these are seldom durable and survival 
is generally less than 12 months although a small 
series suggests the addition of high-dose MTX may 
improve outcome
107. Interestingly, a patient treated 
with a combination of zidovudine and -interferon 
(-IFN) entered into durable remission after only 5 
days
108. Study of the primary tumour cells derived 
from this patient demonstrated that azidothymidine
(AZT) blocked nuclear translocation of NFkB and 
potentiated the pro-apoptotic effect of a-IFN (which 
induces  another  death  receptor  ligand,  TRAIL). 
Further clinical studies of this combinationare under 
way.  In  a  murine  system  sirolimus  showed 
promising activity which was in part mediated by
inhibition of IL-10 signaling
108. Given the relative 
rarity of this lymphoma, patients should be enrolled 
in  clinical  trials  where  possible.  Concomitant 
administration of HAART is advised and there are 
several  reports  of  remission  of  PEL  with  use  of 
HAART alone.
Plasmablastic lymphoma of the oral cavity type: 
Plasmablastic lymphoma is a distinct type of diffuse 
large B-cell lymphoma that occurs most often in the 
oral  cavity  or  jaw  of  HIV-infected  individuals
110. 
This rare lymphoma subtype accounts for 2.6% of 
HIV-related NHL
111 The first description designated 
this  tumour  as  a  lymphoma  of  the  oral  cavity68; 
however,  subsequent  reports  have  described  less 
frequent involvement of extraoral sites such as the 
anal  cavity,  gastrointestinal  tract,  lung,  paranasal 
sinus, skin, spermatic cord, testicle, bone and lymph 
nodes
112-118.
Regardless  of  the  site  of  occurrence, 
plasmablastic  lymphoma  shows  similar 
morphological  and  phenotypic  features.  The 
neoplastic  cells  are  intermediate  to  large  in  size, 
with  round  nuclear  contours  and  occasional 
multinucleation  .  Plasmacytic  differentiation  is 
usually  apparent,  with  a  cytological  spectrum 
including a minor population of small plasmacytoid 
cells  with  condensed  chromatin  ranging  to  large 
cells  with  dispersed  chromatin,  prominent  central 
nucleoli and abundant basophilic cytoplasm with a 
paranuclear hof
112,113,114. The neoplastic population 
generally expresses CD45 and plasmacytic markers 
such  as  CD138,  EMA  and  MUM1,  and  usually 
lacks  expression  of  pan-B-cell  antigens  such  as 
CD20 and  PAX5.1
110,116.  In early reports, slightly 
more  than  50%  of  cases  were  EBER  positive  as 
shown  by  in  situ  hybridisation  studies
110 in  more Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
recent series all cases of plasmablastic lymphoma 
have been shown to be EBER positive
115, 73 EBER-
positive cases generally lack expression of EBNA2 
and  LMP-1
115,116 (Table  2,  Table  3).  HHV8 
infection  is  not  implicated  in  the  pathogenesis  of 
plasmablastic lymphoma, with all cases negative for 
LNA1  when  tested  by  immunohistochemistry. 
While  there  is  morphological  and  phenotypic 
overlap  with  anaplastic  myeloma,  extramedullary 
presentation  and  frequent  EBV  infection  are 
distinctive features. A potential role for EBV in the 
pathogenesis  of  the  disease  remains  unknown, 
especially  with  the  highly  restricted  latency 
expression  pattern.  Despite  the  use  of  aggressive 
chemoteraphy and HAART the prognosis remains 
poor
119.
Polymorphic  B-cell  Lymphoma  (PTLD-like): 
HIV  infection  results  in  a  reduction  of  T-cell 
immunity similar to that iatrogenically induced in 
transplant  patients.  Is  not  surprising  that 
polymorphic  lymphoid  proliferations  resembling 
post-transplant  lymphoproliferative  disorders 
(PTLD) have been reported in HIV-infected adults 
and children.  According to the WHO classification, 
they  are  divided  into  early  lesions  (reactive 
plasmacytic  hyperplasia  and  mononucleosis-like 
syndrome),  polymorphic  lesions,  monomorphic 
lesions,  and  Hodgkin-like  lesions
120.  Similarly  to 
PTLD,  these  infiltrates  are  often  associated  with 
EBV  infection.  By  contrast  with  HIV-associated 
lymphoma, these polymorphic infiltrates often show 
more  limited  disease  distribution,  lack  oncogene 
and tumour suppressor gene alterations, and may be 
polyclonal  or  show  a  minor  B-cell  clone  in  a 
polyclonal background. Regression of polymorphic 
B-cell lymphoma in  an HIV-infected  patient after 
anti-retroviral therapy has been reported
121.
EBV  has  been  linked  to  most  PTLDs,  with  a 
near 100% association in the early-occurring cases 
(within  a  year)  and  in  PTLD-associated  Hodgkin 
lymphoma
122. The EBV-negative PTLDs constitute 
approximately 20% of all cases, have a tendency to 
late  occurrence  and  have  an  unknown  etiology. 
Type III latency is exhibited by the EBV-positive B 
cells in PTLD, although some studies have reported 
a  more  restricted  latency  pattern
123.  The  wide 
expression  of  the  latent  EBV-encoded  proteins 
strongly suggests an important role that EBV may 
play in the oncogenic process (Table 2, Table 3).
The  mechanism  by  which  EBV  is  thought  to 
contribute to the pathogenesis of PTLD is similar to 
its presumed role in Hodgkin lymphoma. Because 
approximately 50% of PTLD cases are derived from 
GC B  cells  lacking a  functional BCR because  of 
certain crippling mutations, and because these cells 
manage to escape apoptosis despite lacking antigen 
affinity,  it  is  believed  that  EBV  aids  in  rescuing 
these  cells  from  an  imminent  programmed  cell 
death
124,125.  As  in  Hodgkin  cases,  LMP1  and 
LMP2A  may  replace  survival  signals  induced  by 
activated  BCR  and  CD40  receptors  and  also 
activate  the  NF-κB  signaling  pathway,  inducing 
proliferation  of  neoplastic  cells.  The  decreased 
cytotoxic  T-cell  surveillance  because  of 
immunosuppression  in  PTLD  patients  is  also 
believed  to  greatly  facilitate  the  actions  of  EBV. 
The  similar  role  that  EBV  is  thought to  play  in 
inducing the survival and neoplastic transformation 
of  infected  GC cells  in  both  PTLD and  Hodgkin 
lymphoma,  in  addition  to  the  near  100%  EBV 
positivity in PTLD-associated Hodgkin lymphoma, 
has led some investigators to speculate a connection 
between the 2 diseases and the possibility that EBV 
infection and its GC effects may be the initiating 
role in the pathogenesis of both entities
124.
Conclusions: HIV-associated lymphomas represent 
a  particular  setting  characterizing  specific 
pathogenetic  models  prevalently  driven  by  EBV 
and by immunodeficiency. The impact of combined 
antiretroviral therapy has substantially changed the 
risk  and  prognosis  of  lymphoma  in  HIV-infected 
population,  as  well  as  the  relationship  with  the 
natural history of HIV disease. As a consequence of 
cART, many authors now strongly recommend that 
patients with lymphoma and HIV infection should 
be treated as patients with lymphoma of the general 
population.
In fact, due to the improvement of morbidity and 
mortality  related  with  cart  exposure,  more 
aggressive  treatment  protocols  can  be  taken  into 
consideration, on the bases of the results in terms of 
efficacy  and  tolerability  reported  in  the  general 
population,  such  as  the  use  of  high-dose 
chemotherapy  in  combination  with  PBSC 
transplantation  in  HIV-NHL  which  showed 
response  rates  similar  to  those  obtained  in  HIV-
negative patients.
The concurrent use of antiblastic chemotherapy 
and  cART should  be  considered  a  potential 
advantage for tumor prognosis and for reducing risk 
of toxicities associated to antineoplastic drugs, even 
though concerns due to drug-drug interactions could 
be  suggested.  In  perspectives,  the  molecular  and 
epidemiological  linkage  between  AIDS-related 
malignancies and EBV-infection suggests that viral 
gene  products  would  be  potential  targets  for Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
molecular-targeted  chemotherapy.  Detailed 
understanding  of  the  EBV    lifecycle  and  related 
cancers  at  the  molecular  level  may  lead to  the 
development  of  novel  strategies  of  molecular-
targeted  cancer  chemotherapy  to  specific  viral 
oncogenes  to  which  the  lymphoma  cells  are 
addicted, and that will provide therapeutic benefits.
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